Name

Sms Pharmaceuticals

Legal name

SMS Pharmaceuticals Limited

Website

https://smspharma.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical intermediates
• Contract manufacturing services
• Generic drug substances
• Impurity reference standards

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. API Manufacturing and Sales: Core revenue from manufacturing and sale of Active Pharmaceutical Ingredients (APIs) across therapeutic segments including Anti-Ulcer, Anti-Migraine, Erectile Dysfunction, Anti-Fungal, and Anti-Emetic categories. Revenue from direct API sales to pharmaceutical companies globally.
2. Contract Manufacturing (CRAMS): Contract manufacturing of API and Intermediates for multinational customers. Services include exclusive manufacturing for clients, collaborative manufacturing with leased production blocks, and joint venture manufacturing partnerships. The company supports customers from late-stage lifecycle through commercial manufacturing.
3. Contract Research Services: Provides contract research/custom synthesis services to pharmaceutical majors including synthetic feasibility studies, route selection, process development, scale up, and lead optimization. Services provided from DSIR-recognized R&D centers.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels3 records

Core offering

SMS Pharmaceuticals Limited manufactures Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and impurity reference standards for the global pharmaceutical industry. The company operates three USFDA-inspected manufacturing facilities in Hyderabad and offers integrated Contract Research and Manufacturing Services (CRAMS), including process research, custom synthesis, scale-up, and commercial API production, serving generic and innovator drug companies across 75+ countries.

Product overview

SMS Pharmaceuticals Ltd is an integrated pharmaceutical company specializing in API (Active Pharmaceutical Ingredients) manufacturing with four multi-product facilities and two research centers. The company offers a portfolio of products including APIs across therapeutic segments (Anti-Ulcer, Anti-Fungal, Anti-Migraine, Erectile Dysfunction, Anti-Emetic), pharmaceutical intermediates, impurity standards, and analytical services through its Central Laboratory Analytical Services (CLAS). The company also provides CRAMS (Contract Research and Manufacturing Services) for custom synthesis and contract manufacturing to pharmaceutical majors.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) Bulk drug substances manufactured under cGMP for generic and innovator pharmaceutical companies serving therapeutic areas such as anti-infectives, cardiovascular, central nervous system, anti-diabetics, and oncology.
• Pharmaceutical Intermediates Chemical intermediates and key starting materials produced for captive API manufacturing and for sale to other API manufacturers requiring documented quality and regulatory support.
• Impurity Reference Standards Characterized impurity standards and related substances supplied to pharmaceutical R&D, quality control labs, and regulatory submissions for generic and innovator drug development.
• Contract Research and Manufacturing Services (CRAMS) End-to-end custom synthesis, process research, and contract manufacturing services for innovator and specialty pharma clients requiring tailored small-molecule development and commercial supply.
• Central Laboratory Analytical Services (CLAS) Analytical and quality control services including method development, validation, impurity profiling, stability studies, and release testing offered to pharmaceutical clients.

Quantifiable outcome

• Largest manufacturer of Ranitidine API in the world since 1995
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• CHEMOcoreStrategic or Co-development Partner · 1 January 2017European partner for joint venture developing 8 products. Products were developed in SMS R&D center and commercialized in Vizianagaram facility. Joint venture was driven by Vamsi Krishna Potluri.
• VKT PharmacoreStrategic or Co-development Partner · 1 January 2015VKT Pharma is a subsidiary concern of SMS Pharmaceuticals manufacturing finished formulations. Vamsi Krishna Potluri, Executive Director of SMS, has been driving VKT's entire operations since 2015. VKT received US FDA approval for reformulated Ranitidine tablets and completed joint venture with US-based ACIC Pharmaceuticals.
• ACIC PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2015Joint venture with US-based ACIC Pharmaceuticals for developing 4 products that have been successfully commercialized and are currently driving revenues of VKT Pharma.
• SMS Peptides Private LimitedcoreStrategic or Co-development PartnerWholly-owned subsidiary of SMS Pharmaceuticals. The Board approved a ₹50 crore loan to subsidiary SMS Peptides. Subsidiary company has its own annual report and corporate announcements.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Laurus Labs: Indian API and CRAMS company with similar small-molecule API focus and growing CDMO franchise. Direct comparable to SMS in serving generic pharma manufacturers and multinational pharma CRAMS customers across similar therapeutic categories.
• Natco Pharma: Indian pharmaceutical company with API manufacturing and specialty generics focus. Comparable to SMS in API manufacturing capabilities, regulatory approvals, and serving both Indian and global generic pharmaceutical customers.
• Ipca Laboratories: Indian pharmaceutical company with significant API manufacturing operations across multiple therapeutic segments. Comparable to SMS in API portfolio breadth, manufacturing scale, and regulatory positioning across USFDA-approved facilities.
• Alkem Laboratories:
• Aurobindo Pharma: Major Indian generic API and finished formulation manufacturer with extensive USFDA-approved manufacturing capacity and a comparable multi-therapeutic API portfolio. SMS Pharma competes with Aurobindo in the same small-molecule generic API space across similar therapeutic categories.
• Divis Laboratories: Indian API-focused manufacturer specializing in generic APIs and intermediates with strong USFDA compliance record. Comparable to SMS in API scale, multi-product facilities, and CDMO offerings; one of SMS's independent directors previously served on Divis's board.
• Granules India: Indian API and finished dosage manufacturer with vertically integrated operations. Direct comparable to SMS in offering APIs, intermediates, and formulations with strong USFDA compliance, particularly in high-volume molecules like Paracetamol.

Broad incumbents

• Sun Pharmaceutical Industries: India's largest pharmaceutical company with broad API, formulation, and specialty drug operations globally. While SMS is much smaller and more focused, Sun Pharma represents a broader incumbent that overlaps with SMS in API supply and contract manufacturing services.
• Cipla: Major Indian pharmaceutical incumbent with global API and finished formulation operations. Comparable to SMS as a potential CRAMS customer and competitor in select API categories, though Cipla operates at significantly larger scale with a much broader portfolio.
• Dr. Reddy's Laboratories: Major Indian pharmaceutical incumbent with significant API operations alongside branded generics and biosimilars. SMS competes with Dr. Reddy's in API manufacturing but operates at much smaller scale in a more focused niche; SMS's founder previously worked at a Dr. Reddy's group company.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCDYFWLOkVQ-8CIdM8JgCXzA
• LinkedInlinkedin.com/company/sms-pharmaceuticals-limited

Compliance14 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sms Pharmaceuticals